跳至主要内容
临床试验/NCT03433768
NCT03433768已完成不适用

Androgen Receptor (AR) mRNA Expression is Positively Associated With Live Birth in Women Undergoing In-vitro Fertilization Independently of the Type of Ovarian Response

Aristotle University Of Thessaloniki0 个研究点目标入组 67 人开始时间: 2014年9月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
67
主要终点
Androgen Receptor mRNA expression

研究概览

简要总结

AR is a steroid hormone receptor that regulates various genes' expression and affects cellular proliferation and differentiation. Androgens interact with AR, exert their paracrine action on granulosa cells and regulate gonadotropin synthesis, follicle development, oocyte maturation and corpus luteum function. Estrogens increase AR mRNA and testosterone binding site in uterine endometrium and leiomyoma. In human cancer cells, low estradiol increases AR levels, suggesting the estrogen/androgen ratio as a predictor of sex steroid response. AR mRNA expression is, also, regulated by progesterone. Although AR mRNA is expressed in the female reproductive tissues, its expression has never been studied in peripheral blood.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
20 Years 至 42 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Women with poor ovarian response according to bologna criteria
  • Advanced maternal age (≥40 years) or any other risk factor for poor ovarian response
  • A previous poor ovarian response (≤3 oocytes with a conventional stimulation protocol)
  • Abnormal ovarian reserve test, (AFC ˂5-7 follicles or AMH ˂0.5-1.1 ng/ml).
  • Women with normal ovarian response with normal menstrual cycles, normal astral follicle count and normal hormonal assay.

排除标准

  • Not more than 43 years old.
  • No history of malignancies, endometriosis or polycystic ovary syndrome.
  • Underlying genetic cause of infertility
  • History of severe cardiac, hepatic or renal disease.
  • History of systemic disease or treatment during the last three (3) months
  • Participation in another interventional study and a likelihood of being unavailable for follow-up.

结局指标

主要结局

Androgen Receptor mRNA expression

时间窗: day one, six and ten of ovarian stimulation

The expression of androgen receptor mRNA in peripheral blood of normal and poor responders level of expression in peripheral blood according to the Delta-Delta-Ct (ddCt) Algorithm. Percentage of increase?

次要结局

  • Serum estradiol levels in peripheral blood of normal and poor responders(day one, six and ten of ovarian stimulation)
  • Serum LH levels in peripheral blood of normal and poor responders(day one, six and ten of ovarian stimulation)
  • Serum progesterone levels in peripheral blood of normal and poor responders.(day one, six and ten of ovarian stimulation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

E.M. Kolibianakis

Associate Professor

Aristotle University Of Thessaloniki

相似试验

招募中
不适用
Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen InsensitivityMetabolic Parameters in AIS, CAIS, PAIS and MAISTumor Formation in AIS, CAIS, PAIS and MAISSexual Function AIS, CAIS, PAIS and MAISAndrogen Insensitivity Syndrome
NCT04708431Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)650
撤回
不适用
Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)Prostate Cancer
NCT03296124University of Florida
已完成
不适用
of Androgen Receptor Expression in Breast Cancer With or Without BRCA MutationBreast Cancer
NCT05404334Banaras Hindu University231
进行中(未招募)
1 期
Dynamics of Androgen Receptor.MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036920Term: Prostate cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036911Term: Prostate cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036912Term: Prostate cancer stage 0System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036917Term: Prostate cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036919Term: Prostate cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10036918Term: Prostate cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Prostate cancer
EUCTR2014-000476-26-NLetherlands Cancer Institute50
尚未招募
2 期
Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA)prostate cancerprostate carcinoma10038597
NL-OMON40287Antoni van Leeuwenhoek Ziekenhuis60